| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 129 | 2021 | 358 | 23.120 |
Why?
|
| Anticholesteremic Agents | 94 | 2020 | 137 | 17.160 |
Why?
|
| Cholesterol, LDL | 124 | 2019 | 210 | 15.480 |
Why?
|
| Dyslipidemias | 56 | 2021 | 106 | 14.960 |
Why?
|
| Cardiovascular Diseases | 90 | 2021 | 767 | 14.560 |
Why?
|
| Hypercholesterolemia | 90 | 2018 | 163 | 13.490 |
Why?
|
| Hypolipidemic Agents | 64 | 2020 | 101 | 12.530 |
Why?
|
| Schizophrenia | 94 | 2021 | 447 | 10.470 |
Why?
|
| Hypertriglyceridemia | 32 | 2021 | 63 | 9.590 |
Why?
|
| Cholesterol, HDL | 79 | 2019 | 164 | 8.650 |
Why?
|
| Fatty Acids, Omega-3 | 26 | 2021 | 50 | 8.600 |
Why?
|
| Coronary Disease | 50 | 2018 | 269 | 6.870 |
Why?
|
| Atherosclerosis | 25 | 2021 | 219 | 6.610 |
Why?
|
| Triglycerides | 63 | 2020 | 232 | 6.300 |
Why?
|
| Coronary Artery Disease | 33 | 2019 | 323 | 6.210 |
Why?
|
| Schizophrenic Psychology | 61 | 2019 | 127 | 5.880 |
Why?
|
| Antipsychotic Agents | 39 | 2019 | 116 | 5.520 |
Why?
|
| Azetidines | 26 | 2013 | 37 | 5.410 |
Why?
|
| Lipids | 48 | 2019 | 276 | 5.410 |
Why?
|
| Simvastatin | 44 | 2019 | 106 | 5.340 |
Why?
|
| Hyperlipidemias | 29 | 2014 | 98 | 4.850 |
Why?
|
| Heptanoic Acids | 35 | 2014 | 73 | 4.490 |
Why?
|
| Niacin | 25 | 2014 | 37 | 4.330 |
Why?
|
| Fenofibrate | 18 | 2014 | 21 | 4.330 |
Why?
|
| Humans | 589 | 2021 | 79512 | 4.310 |
Why?
|
| Double-Blind Method | 128 | 2021 | 1778 | 4.230 |
Why?
|
| Pyrroles | 35 | 2014 | 184 | 4.140 |
Why?
|
| Cholesterol | 44 | 2020 | 366 | 4.040 |
Why?
|
| Docosahexaenoic Acids | 16 | 2020 | 32 | 3.970 |
Why?
|
| Fluorobenzenes | 24 | 2012 | 33 | 3.940 |
Why?
|
| Drug Therapy, Combination | 65 | 2019 | 902 | 3.930 |
Why?
|
| Risk Factors | 129 | 2020 | 5099 | 3.830 |
Why?
|
| Cognition Disorders | 32 | 2015 | 228 | 3.590 |
Why?
|
| Pyrimidines | 26 | 2012 | 360 | 3.490 |
Why?
|
| Eicosapentaenoic Acid | 13 | 2020 | 17 | 3.440 |
Why?
|
| Sulfonamides | 25 | 2012 | 295 | 3.390 |
Why?
|
| Male | 339 | 2021 | 39419 | 3.170 |
Why?
|
| Middle Aged | 255 | 2021 | 23948 | 3.120 |
Why?
|
| Female | 327 | 2021 | 42244 | 2.940 |
Why?
|
| Allylamine | 10 | 2013 | 11 | 2.900 |
Why?
|
| Treatment Outcome | 111 | 2021 | 7469 | 2.870 |
Why?
|
| Lipoproteins, LDL | 17 | 2016 | 85 | 2.820 |
Why?
|
| Diabetes Mellitus, Type 2 | 28 | 2017 | 1257 | 2.810 |
Why?
|
| Aged | 217 | 2020 | 17394 | 2.800 |
Why?
|
| Indoles | 15 | 2019 | 316 | 2.490 |
Why?
|
| Diabetes Mellitus | 21 | 2016 | 742 | 2.450 |
Why?
|
| Lipoproteins | 26 | 2019 | 140 | 2.410 |
Why?
|
| Rhabdomyolysis | 7 | 2016 | 27 | 2.270 |
Why?
|
| Hyperlipoproteinemia Type II | 9 | 2018 | 18 | 2.270 |
Why?
|
| Adult | 203 | 2021 | 24525 | 2.270 |
Why?
|
| Cholesterol Ester Transfer Proteins | 16 | 2014 | 19 | 2.210 |
Why?
|
| Clinical Trials as Topic | 37 | 2021 | 1149 | 2.130 |
Why?
|
| Serine Proteinase Inhibitors | 7 | 2019 | 28 | 2.120 |
Why?
|
| Hypoglycemic Agents | 16 | 2015 | 356 | 2.070 |
Why?
|
| Clofibric Acid | 10 | 2009 | 15 | 2.040 |
Why?
|
| Risperidone | 11 | 2012 | 23 | 2.020 |
Why?
|
| Randomized Controlled Trials as Topic | 31 | 2021 | 803 | 2.020 |
Why?
|
| Psychotic Disorders | 15 | 2018 | 172 | 2.020 |
Why?
|
| Antibodies, Monoclonal | 11 | 2018 | 1367 | 1.980 |
Why?
|
| Primary Prevention | 8 | 2018 | 81 | 1.940 |
Why?
|
| Psychiatric Status Rating Scales | 44 | 2018 | 474 | 1.920 |
Why?
|
| Apolipoprotein A-I | 14 | 2015 | 71 | 1.870 |
Why?
|
| Apolipoproteins B | 12 | 2014 | 39 | 1.750 |
Why?
|
| Intestinal Absorption | 8 | 2018 | 122 | 1.720 |
Why?
|
| Risk Assessment | 35 | 2019 | 2158 | 1.720 |
Why?
|
| Tunica Intima | 10 | 2011 | 57 | 1.690 |
Why?
|
| Antibodies, Monoclonal, Humanized | 10 | 2020 | 898 | 1.670 |
Why?
|
| Alzheimer Disease | 33 | 2005 | 328 | 1.660 |
Why?
|
| Dietary Supplements | 10 | 2020 | 122 | 1.590 |
Why?
|
| Thiazolidinediones | 7 | 2012 | 81 | 1.590 |
Why?
|
| Dementia | 16 | 2008 | 164 | 1.580 |
Why?
|
| Lipoproteins, HDL | 12 | 2016 | 96 | 1.570 |
Why?
|
| Molecular Targeted Therapy | 5 | 2018 | 256 | 1.510 |
Why?
|
| Muscular Diseases | 10 | 2017 | 59 | 1.500 |
Why?
|
| Lovastatin | 12 | 2005 | 28 | 1.470 |
Why?
|
| Carotid Artery Diseases | 7 | 2015 | 91 | 1.460 |
Why?
|
| Diet, Fat-Restricted | 7 | 2020 | 31 | 1.450 |
Why?
|
| Hyperlipoproteinemia Type I | 2 | 2018 | 2 | 1.380 |
Why?
|
| Haloperidol | 12 | 2006 | 30 | 1.370 |
Why?
|
| Carotid Arteries | 8 | 2014 | 125 | 1.370 |
Why?
|
| Dose-Response Relationship, Drug | 43 | 2018 | 1969 | 1.350 |
Why?
|
| Cost of Illness | 4 | 2018 | 145 | 1.350 |
Why?
|
| Inflammation | 10 | 2020 | 819 | 1.330 |
Why?
|
| Fatty Acids, Nonesterified | 7 | 2017 | 72 | 1.330 |
Why?
|
| Nonprescription Drugs | 4 | 2018 | 15 | 1.320 |
Why?
|
| Drug Administration Schedule | 28 | 2018 | 931 | 1.310 |
Why?
|
| Carboxylic Acids | 5 | 2018 | 15 | 1.300 |
Why?
|
| Diabetic Angiopathies | 5 | 2011 | 63 | 1.290 |
Why?
|
| Fatty Acids, Omega-6 | 3 | 2018 | 9 | 1.280 |
Why?
|
| Quinolines | 5 | 2014 | 90 | 1.260 |
Why?
|
| Esophageal Neoplasms | 3 | 2019 | 302 | 1.260 |
Why?
|
| Diabetes Complications | 9 | 2013 | 207 | 1.250 |
Why?
|
| Practice Guidelines as Topic | 20 | 2017 | 1030 | 1.250 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 5 | 2011 | 39 | 1.220 |
Why?
|
| Obesity | 15 | 2015 | 907 | 1.180 |
Why?
|
| Pravastatin | 9 | 2014 | 17 | 1.140 |
Why?
|
| Proprotein Convertases | 4 | 2013 | 24 | 1.140 |
Why?
|
| Metabolic Diseases | 2 | 2018 | 46 | 1.120 |
Why?
|
| Time Factors | 47 | 2019 | 5143 | 1.090 |
Why?
|
| C-Reactive Protein | 16 | 2015 | 183 | 1.090 |
Why?
|
| Severity of Illness Index | 30 | 2020 | 1686 | 1.080 |
Why?
|
| Carotid Intima-Media Thickness | 6 | 2015 | 38 | 1.070 |
Why?
|
| Oxazolidinones | 6 | 2014 | 11 | 1.070 |
Why?
|
| Follow-Up Studies | 42 | 2019 | 3553 | 1.060 |
Why?
|
| Aged, 80 and over | 63 | 2018 | 6195 | 1.060 |
Why?
|
| Neuropsychological Tests | 26 | 2015 | 429 | 1.050 |
Why?
|
| Cardiology | 5 | 2012 | 118 | 1.030 |
Why?
|
| Biological Availability | 11 | 2017 | 97 | 1.030 |
Why?
|
| Adolescent | 58 | 2018 | 8657 | 1.030 |
Why?
|
| Mental Disorders | 10 | 2018 | 360 | 1.030 |
Why?
|
| Carotid Artery, Common | 3 | 2015 | 28 | 1.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2019 | 2277 | 1.000 |
Why?
|
| Hospitalization | 23 | 2016 | 748 | 0.970 |
Why?
|
| Arteriosclerosis | 10 | 2008 | 158 | 0.960 |
Why?
|
| Blood Glucose | 16 | 2015 | 850 | 0.960 |
Why?
|
| Risk | 17 | 2018 | 669 | 0.930 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 1111 | 0.920 |
Why?
|
| Carrier Proteins | 7 | 2014 | 662 | 0.910 |
Why?
|
| Postmenopause | 12 | 2005 | 88 | 0.910 |
Why?
|
| Drug Combinations | 14 | 2014 | 223 | 0.890 |
Why?
|
| Diet | 13 | 2017 | 427 | 0.880 |
Why?
|
| Homovanillic Acid | 12 | 1994 | 34 | 0.870 |
Why?
|
| Colchicine | 1 | 2021 | 28 | 0.870 |
Why?
|
| United States | 35 | 2020 | 6050 | 0.860 |
Why?
|
| Intelligence | 6 | 2015 | 69 | 0.850 |
Why?
|
| Sterols | 2 | 2018 | 13 | 0.850 |
Why?
|
| Kidney Failure, Chronic | 3 | 2020 | 500 | 0.850 |
Why?
|
| Esters | 5 | 2017 | 24 | 0.830 |
Why?
|
| Flushing | 6 | 2009 | 7 | 0.820 |
Why?
|
| Cohort Studies | 25 | 2017 | 2561 | 0.810 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 242 | 0.810 |
Why?
|
| Gemfibrozil | 5 | 2012 | 8 | 0.810 |
Why?
|
| Anemia | 2 | 2020 | 124 | 0.800 |
Why?
|
| Israel | 18 | 2017 | 56 | 0.790 |
Why?
|
| Vitamins | 5 | 2014 | 71 | 0.770 |
Why?
|
| Lipoprotein(a) | 6 | 2020 | 27 | 0.770 |
Why?
|
| Suicide | 3 | 2016 | 137 | 0.770 |
Why?
|
| Bile Acids and Salts | 4 | 2011 | 46 | 0.760 |
Why?
|
| Prospective Studies | 29 | 2019 | 3870 | 0.760 |
Why?
|
| Tunica Media | 5 | 2011 | 16 | 0.750 |
Why?
|
| Kidney Diseases | 5 | 2018 | 407 | 0.750 |
Why?
|
| Dietary Fiber | 8 | 2007 | 42 | 0.730 |
Why?
|
| Nutritional Sciences | 1 | 2018 | 11 | 0.730 |
Why?
|
| Retrospective Studies | 27 | 2019 | 7386 | 0.720 |
Why?
|
| Fasting | 7 | 2020 | 162 | 0.710 |
Why?
|
| Young Adult | 26 | 2019 | 5701 | 0.710 |
Why?
|
| Predictive Value of Tests | 14 | 2019 | 1618 | 0.700 |
Why?
|
| Ibuprofen | 2 | 2018 | 26 | 0.700 |
Why?
|
| Renal Dialysis | 2 | 2020 | 362 | 0.700 |
Why?
|
| Fatty Acids, Monounsaturated | 6 | 2005 | 14 | 0.700 |
Why?
|
| Military Personnel | 6 | 2017 | 71 | 0.700 |
Why?
|
| Naproxen | 1 | 2018 | 12 | 0.700 |
Why?
|
| Comorbidity | 18 | 2019 | 907 | 0.690 |
Why?
|
| Anti-Obesity Agents | 2 | 2013 | 14 | 0.690 |
Why?
|
| Sulfonylurea Compounds | 5 | 2011 | 58 | 0.680 |
Why?
|
| Estrogen Replacement Therapy | 8 | 2005 | 43 | 0.680 |
Why?
|
| Acetaminophen | 1 | 2018 | 53 | 0.680 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 4 | 2006 | 21 | 0.670 |
Why?
|
| Glycoproteins | 5 | 2014 | 237 | 0.670 |
Why?
|
| Research | 2 | 2018 | 249 | 0.670 |
Why?
|
| Arthralgia | 1 | 2017 | 34 | 0.650 |
Why?
|
| Body Weight | 11 | 2014 | 457 | 0.650 |
Why?
|
| Fat Substitutes | 3 | 2014 | 3 | 0.650 |
Why?
|
| Chronic Disease | 25 | 2013 | 932 | 0.650 |
Why?
|
| Patient Discharge | 2 | 2015 | 224 | 0.650 |
Why?
|
| Analgesics | 1 | 2018 | 114 | 0.640 |
Why?
|
| Disease Management | 2 | 2018 | 323 | 0.630 |
Why?
|
| Twins, Monozygotic | 1 | 2016 | 58 | 0.630 |
Why?
|
| Heart Diseases | 3 | 2018 | 288 | 0.620 |
Why?
|
| Patient Selection | 10 | 2013 | 662 | 0.610 |
Why?
|
| Indians, North American | 8 | 2013 | 48 | 0.610 |
Why?
|
| Registries | 11 | 2016 | 648 | 0.610 |
Why?
|
| Phytosterols | 4 | 2006 | 6 | 0.610 |
Why?
|
| Blood Pressure | 13 | 2015 | 1141 | 0.610 |
Why?
|
| Medical Laboratory Science | 2 | 2006 | 7 | 0.600 |
Why?
|
| Actins | 8 | 2015 | 429 | 0.600 |
Why?
|
| Fatty Acids | 7 | 2018 | 123 | 0.590 |
Why?
|
| Age Factors | 26 | 2019 | 1797 | 0.590 |
Why?
|
| Psychometrics | 16 | 2017 | 293 | 0.590 |
Why?
|
| Dietary Fats | 7 | 2018 | 142 | 0.580 |
Why?
|
| Serine Endopeptidases | 3 | 2013 | 146 | 0.580 |
Why?
|
| Area Under Curve | 9 | 2020 | 334 | 0.580 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 246 | 0.580 |
Why?
|
| Biological Transport | 3 | 2013 | 396 | 0.580 |
Why?
|
| Beverages | 2 | 2009 | 15 | 0.580 |
Why?
|
| Incretins | 2 | 2014 | 14 | 0.580 |
Why?
|
| Prevalence | 14 | 2016 | 1163 | 0.580 |
Why?
|
| Animals | 51 | 2020 | 25594 | 0.580 |
Why?
|
| Oligonucleotides | 2 | 2013 | 90 | 0.580 |
Why?
|
| Comprehensive Health Care | 1 | 2015 | 12 | 0.570 |
Why?
|
| Stroke | 6 | 2018 | 752 | 0.570 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2014 | 42 | 0.570 |
Why?
|
| Insulin Resistance | 7 | 2013 | 366 | 0.560 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2015 | 20 | 0.560 |
Why?
|
| Glycerides | 1 | 2014 | 15 | 0.550 |
Why?
|
| Intestines | 1 | 2018 | 405 | 0.550 |
Why?
|
| Patient Compliance | 9 | 2014 | 220 | 0.540 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2014 | 14 | 0.540 |
Why?
|
| Cross-Over Studies | 11 | 2020 | 392 | 0.530 |
Why?
|
| Pyridines | 6 | 2012 | 300 | 0.530 |
Why?
|
| Insulin | 9 | 2015 | 1126 | 0.530 |
Why?
|
| Blood Chemical Analysis | 4 | 2012 | 44 | 0.530 |
Why?
|
| Apolipoprotein C-III | 4 | 2020 | 8 | 0.530 |
Why?
|
| Program Evaluation | 2 | 2006 | 285 | 0.520 |
Why?
|
| Disease Progression | 12 | 2016 | 1424 | 0.520 |
Why?
|
| Medical Records Systems, Computerized | 3 | 2009 | 37 | 0.520 |
Why?
|
| Longitudinal Studies | 17 | 2017 | 947 | 0.510 |
Why?
|
| Secondary Prevention | 5 | 2011 | 161 | 0.510 |
Why?
|
| Aging | 7 | 2007 | 623 | 0.510 |
Why?
|
| Cholinesterase Inhibitors | 5 | 2004 | 43 | 0.510 |
Why?
|
| Genetic Variation | 4 | 2019 | 1314 | 0.500 |
Why?
|
| Dopamine Antagonists | 2 | 2012 | 34 | 0.500 |
Why?
|
| Phentermine | 1 | 2013 | 4 | 0.500 |
Why?
|
| Algorithms | 12 | 2020 | 1768 | 0.490 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 4 | 2002 | 16 | 0.490 |
Why?
|
| Fructose | 1 | 2013 | 34 | 0.490 |
Why?
|
| Immunotherapy | 1 | 2018 | 545 | 0.490 |
Why?
|
| Quality of Life | 5 | 2017 | 1342 | 0.480 |
Why?
|
| Social Adjustment | 6 | 2019 | 45 | 0.480 |
Why?
|
| GABA Agonists | 1 | 2012 | 17 | 0.480 |
Why?
|
| Delayed-Action Preparations | 10 | 2013 | 118 | 0.480 |
Why?
|
| Lipid Metabolism | 4 | 2015 | 190 | 0.480 |
Why?
|
| Cytomegalovirus Retinitis | 2 | 2002 | 7 | 0.480 |
Why?
|
| Sex Factors | 13 | 2019 | 1021 | 0.470 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2002 | 35 | 0.470 |
Why?
|
| Hypertension | 10 | 2008 | 1185 | 0.470 |
Why?
|
| Incidence | 14 | 2018 | 1528 | 0.460 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2012 | 81 | 0.460 |
Why?
|
| Risk Reduction Behavior | 4 | 2009 | 101 | 0.460 |
Why?
|
| Health Surveys | 3 | 2013 | 228 | 0.460 |
Why?
|
| Coronary Vessels | 5 | 2008 | 180 | 0.460 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2002 | 158 | 0.450 |
Why?
|
| Population Surveillance | 6 | 2006 | 218 | 0.440 |
Why?
|
| Estradiol | 4 | 2019 | 246 | 0.440 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2009 | 121 | 0.430 |
Why?
|
| Patient Admission | 6 | 2017 | 105 | 0.430 |
Why?
|
| Bipolar Disorder | 3 | 2012 | 370 | 0.430 |
Why?
|
| Calcinosis | 2 | 2010 | 232 | 0.430 |
Why?
|
| Cardiovascular System | 1 | 2011 | 68 | 0.420 |
Why?
|
| Prognosis | 18 | 2013 | 3522 | 0.420 |
Why?
|
| Central Nervous System Infections | 1 | 2010 | 3 | 0.420 |
Why?
|
| Farnesyl-Diphosphate Farnesyltransferase | 2 | 2009 | 5 | 0.420 |
Why?
|
| Cell Movement | 5 | 2015 | 733 | 0.420 |
Why?
|
| Adaptation, Psychological | 6 | 2019 | 151 | 0.420 |
Why?
|
| Drug Interactions | 9 | 2017 | 250 | 0.420 |
Why?
|
| Cell Polarity | 3 | 2016 | 113 | 0.420 |
Why?
|
| Administration, Oral | 11 | 2013 | 686 | 0.410 |
Why?
|
| Child, Hospitalized | 1 | 2010 | 28 | 0.410 |
Why?
|
| Paclitaxel | 3 | 1997 | 442 | 0.410 |
Why?
|
| Regression Analysis | 8 | 2015 | 588 | 0.400 |
Why?
|
| Safety | 8 | 2017 | 157 | 0.400 |
Why?
|
| Cholesterol, VLDL | 6 | 2015 | 14 | 0.400 |
Why?
|
| Lythraceae | 1 | 2009 | 1 | 0.400 |
Why?
|
| Betaine | 1 | 2009 | 4 | 0.400 |
Why?
|
| Nicotine | 3 | 2004 | 165 | 0.390 |
Why?
|
| Vasodilator Agents | 4 | 2015 | 163 | 0.390 |
Why?
|
| Health Care Costs | 2 | 2010 | 225 | 0.390 |
Why?
|
| Homocysteine | 1 | 2009 | 28 | 0.390 |
Why?
|
| Piperidines | 3 | 2009 | 171 | 0.380 |
Why?
|
| Psyllium | 3 | 2000 | 3 | 0.380 |
Why?
|
| Microtubules | 3 | 2015 | 115 | 0.380 |
Why?
|
| Physician's Role | 1 | 2011 | 177 | 0.380 |
Why?
|
| Body Composition | 3 | 2007 | 65 | 0.380 |
Why?
|
| Intelligence Tests | 2 | 2006 | 38 | 0.380 |
Why?
|
| Quinazolines | 1 | 2011 | 217 | 0.380 |
Why?
|
| Phytotherapy | 2 | 2011 | 129 | 0.380 |
Why?
|
| Refractive Errors | 1 | 2008 | 4 | 0.370 |
Why?
|
| Cognition | 9 | 2018 | 491 | 0.370 |
Why?
|
| Body Mass Index | 10 | 2016 | 740 | 0.370 |
Why?
|
| Organophosphorus Compounds | 1 | 2009 | 54 | 0.370 |
Why?
|
| Evidence-Based Medicine | 5 | 2011 | 422 | 0.370 |
Why?
|
| Ultrasonography, Interventional | 2 | 2008 | 106 | 0.370 |
Why?
|
| Aspirin | 3 | 2021 | 141 | 0.370 |
Why?
|
| Intestinal Mucosa | 2 | 2014 | 794 | 0.370 |
Why?
|
| Forecasting | 4 | 2012 | 302 | 0.370 |
Why?
|
| Pancreatitis | 2 | 2020 | 83 | 0.360 |
Why?
|
| Focal Adhesions | 3 | 2014 | 69 | 0.360 |
Why?
|
| Spironolactone | 1 | 2008 | 23 | 0.360 |
Why?
|
| Carotid Stenosis | 1 | 2009 | 102 | 0.360 |
Why?
|
| Health Expenditures | 1 | 2010 | 85 | 0.360 |
Why?
|
| Glucans | 2 | 2003 | 9 | 0.360 |
Why?
|
| Analysis of Variance | 16 | 2013 | 899 | 0.350 |
Why?
|
| Benzamides | 1 | 2009 | 219 | 0.350 |
Why?
|
| Apolipoproteins | 10 | 2012 | 37 | 0.350 |
Why?
|
| Patient Education as Topic | 3 | 2002 | 340 | 0.350 |
Why?
|
| Inuits | 7 | 2005 | 10 | 0.350 |
Why?
|
| Myocardial Ischemia | 2 | 2009 | 150 | 0.340 |
Why?
|
| Circadian Rhythm | 4 | 2008 | 291 | 0.340 |
Why?
|
| Prostatic Neoplasms | 2 | 2019 | 1525 | 0.340 |
Why?
|
| Albuminuria | 1 | 2008 | 143 | 0.330 |
Why?
|
| Cross-Sectional Studies | 11 | 2017 | 1367 | 0.330 |
Why?
|
| Carotid Artery, Internal | 1 | 2007 | 65 | 0.330 |
Why?
|
| Smoking | 5 | 2004 | 549 | 0.330 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2019 | 160 | 0.330 |
Why?
|
| Benzimidazoles | 3 | 2014 | 135 | 0.330 |
Why?
|
| Social Class | 2 | 2007 | 122 | 0.330 |
Why?
|
| Fish Oils | 4 | 2008 | 12 | 0.330 |
Why?
|
| Glycemic Index | 1 | 2007 | 10 | 0.330 |
Why?
|
| Cholagogues and Choleretics | 3 | 2006 | 10 | 0.330 |
Why?
|
| Smoking Cessation | 2 | 1999 | 175 | 0.330 |
Why?
|
| Enzyme Inhibitors | 6 | 2009 | 626 | 0.320 |
Why?
|
| Geriatric Assessment | 7 | 2005 | 155 | 0.320 |
Why?
|
| Drug Prescriptions | 3 | 2016 | 135 | 0.320 |
Why?
|
| Cholelithiasis | 1 | 2006 | 31 | 0.320 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 248 | 0.320 |
Why?
|
| Isoxazoles | 1 | 2007 | 78 | 0.320 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2006 | 35 | 0.320 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 419 | 0.320 |
Why?
|
| Antibodies, Bacterial | 4 | 2013 | 92 | 0.310 |
Why?
|
| Cell Adhesion | 5 | 2015 | 413 | 0.300 |
Why?
|
| Reference Values | 12 | 2009 | 653 | 0.300 |
Why?
|
| Ovarian Neoplasms | 3 | 1997 | 673 | 0.300 |
Why?
|
| Prediabetic State | 4 | 2015 | 38 | 0.300 |
Why?
|
| Age of Onset | 4 | 2019 | 309 | 0.300 |
Why?
|
| Sterol O-Acyltransferase | 4 | 2011 | 11 | 0.300 |
Why?
|
| Drug Compounding | 2 | 2016 | 73 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2019 | 2148 | 0.290 |
Why?
|
| Pneumococcal Infections | 4 | 1996 | 45 | 0.290 |
Why?
|
| Dietary Fats, Unsaturated | 4 | 2002 | 7 | 0.290 |
Why?
|
| Estrogens | 3 | 2019 | 184 | 0.290 |
Why?
|
| Cholesterol Esters | 2 | 2003 | 14 | 0.290 |
Why?
|
| Cytoskeleton | 3 | 2016 | 185 | 0.290 |
Why?
|
| Blood Platelets | 2 | 2017 | 148 | 0.290 |
Why?
|
| Lactones | 3 | 2000 | 30 | 0.280 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 172 | 0.280 |
Why?
|
| Vaccines, Synthetic | 2 | 2003 | 54 | 0.280 |
Why?
|
| Proteinuria | 2 | 2006 | 108 | 0.280 |
Why?
|
| Sensitivity and Specificity | 9 | 2018 | 1937 | 0.280 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 2004 | 6 | 0.280 |
Why?
|
| Dopamine | 9 | 1994 | 261 | 0.280 |
Why?
|
| Fluorescent Dyes | 3 | 2015 | 240 | 0.280 |
Why?
|
| Intermediate Filaments | 2 | 2015 | 16 | 0.280 |
Why?
|
| Vinculin | 2 | 2015 | 9 | 0.280 |
Why?
|
| Adipose Tissue | 4 | 2009 | 234 | 0.270 |
Why?
|
| Survival Rate | 8 | 2011 | 1809 | 0.270 |
Why?
|
| Vimentin | 2 | 2015 | 45 | 0.270 |
Why?
|
| Maximum Tolerated Dose | 2 | 2018 | 258 | 0.270 |
Why?
|
| India | 3 | 2016 | 124 | 0.270 |
Why?
|
| United States Food and Drug Administration | 5 | 2008 | 119 | 0.270 |
Why?
|
| Mental Status Schedule | 5 | 1997 | 24 | 0.270 |
Why?
|
| Hospitals, Psychiatric | 4 | 2016 | 23 | 0.270 |
Why?
|
| Electrolytes | 2 | 2004 | 54 | 0.270 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2004 | 8 | 0.270 |
Why?
|
| Consensus | 4 | 2020 | 288 | 0.270 |
Why?
|
| Interleukin-6 | 3 | 2020 | 226 | 0.270 |
Why?
|
| Apolipoprotein B-100 | 4 | 2018 | 11 | 0.270 |
Why?
|
| Research Design | 6 | 2018 | 559 | 0.270 |
Why?
|
| Chlamydophila pneumoniae | 3 | 2013 | 12 | 0.270 |
Why?
|
| Skin | 1 | 2008 | 538 | 0.270 |
Why?
|
| Dicarboxylic Acids | 2 | 2014 | 22 | 0.260 |
Why?
|
| Terminology as Topic | 1 | 2006 | 214 | 0.260 |
Why?
|
| Frontal Lobe | 6 | 2006 | 120 | 0.260 |
Why?
|
| Nootropic Agents | 1 | 2004 | 10 | 0.260 |
Why?
|
| Indans | 1 | 2004 | 19 | 0.260 |
Why?
|
| Developmental Disabilities | 1 | 2005 | 190 | 0.260 |
Why?
|
| Child | 17 | 2017 | 6481 | 0.260 |
Why?
|
| Food, Fortified | 1 | 2003 | 7 | 0.260 |
Why?
|
| Eggs | 1 | 2003 | 11 | 0.260 |
Why?
|
| Phospholipases A2 | 2 | 2015 | 44 | 0.260 |
Why?
|
| Peptides | 3 | 2020 | 619 | 0.260 |
Why?
|
| Peripheral Arterial Disease | 2 | 2018 | 74 | 0.260 |
Why?
|
| Acute Kidney Injury | 2 | 2004 | 264 | 0.260 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 164 | 0.260 |
Why?
|
| Lipase | 2 | 2004 | 21 | 0.250 |
Why?
|
| Alaska | 12 | 2013 | 16 | 0.250 |
Why?
|
| Reproducibility of Results | 12 | 2017 | 2570 | 0.250 |
Why?
|
| Dangerous Behavior | 1 | 2003 | 4 | 0.250 |
Why?
|
| Phenotype | 6 | 2019 | 2246 | 0.250 |
Why?
|
| Liver | 6 | 2015 | 1191 | 0.250 |
Why?
|
| Adolescent Behavior | 1 | 2004 | 100 | 0.250 |
Why?
|
| Brain Ischemia | 1 | 2007 | 311 | 0.250 |
Why?
|
| Half-Life | 5 | 2020 | 98 | 0.250 |
Why?
|
| Language Disorders | 1 | 2002 | 6 | 0.250 |
Why?
|
| Survival Analysis | 5 | 2018 | 1519 | 0.250 |
Why?
|
| Multivariate Analysis | 6 | 2013 | 962 | 0.250 |
Why?
|
| Luminescent Proteins | 2 | 2015 | 147 | 0.240 |
Why?
|
| Activities of Daily Living | 6 | 2017 | 187 | 0.240 |
Why?
|
| Meat | 2 | 2000 | 26 | 0.240 |
Why?
|
| Estrogens, Conjugated (USP) | 6 | 2002 | 16 | 0.240 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 1181 | 0.240 |
Why?
|
| Guideline Adherence | 2 | 2002 | 215 | 0.240 |
Why?
|
| Autoimmunity | 1 | 2004 | 155 | 0.240 |
Why?
|
| Food | 2 | 2001 | 80 | 0.240 |
Why?
|
| Antihypertensive Agents | 2 | 2007 | 567 | 0.230 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 420 | 0.230 |
Why?
|
| Databases, Factual | 6 | 2015 | 756 | 0.230 |
Why?
|
| Societies, Scientific | 2 | 2013 | 44 | 0.230 |
Why?
|
| Institutionalization | 3 | 2002 | 6 | 0.230 |
Why?
|
| Chlamydia Infections | 2 | 2000 | 24 | 0.230 |
Why?
|
| Mental Recall | 5 | 1997 | 135 | 0.230 |
Why?
|
| Integrins | 2 | 2014 | 73 | 0.230 |
Why?
|
| Proportional Hazards Models | 9 | 2017 | 823 | 0.230 |
Why?
|
| Norethindrone | 2 | 2002 | 12 | 0.230 |
Why?
|
| Hyperlipidemia, Familial Combined | 2 | 2001 | 5 | 0.230 |
Why?
|
| Ultrasonography | 6 | 2011 | 648 | 0.230 |
Why?
|
| Autoantibodies | 1 | 2003 | 249 | 0.230 |
Why?
|
| Diet Records | 4 | 2003 | 19 | 0.230 |
Why?
|
| Anticoagulants | 4 | 2020 | 380 | 0.230 |
Why?
|
| HIV-1 | 1 | 2002 | 131 | 0.220 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2002 | 38 | 0.220 |
Why?
|
| Clozapine | 4 | 1994 | 9 | 0.220 |
Why?
|
| Odds Ratio | 3 | 2012 | 647 | 0.220 |
Why?
|
| Calcium Channel Blockers | 3 | 2003 | 225 | 0.220 |
Why?
|
| Ligands | 2 | 2020 | 417 | 0.220 |
Why?
|
| Parasympathomimetics | 2 | 1991 | 9 | 0.220 |
Why?
|
| Apolipoprotein C-II | 2 | 2020 | 2 | 0.220 |
Why?
|
| Cyclophosphamide | 3 | 1997 | 280 | 0.220 |
Why?
|
| Placebos | 10 | 2021 | 218 | 0.220 |
Why?
|
| Corn Oil | 1 | 2020 | 3 | 0.220 |
Why?
|
| Life Style | 6 | 2013 | 180 | 0.210 |
Why?
|
| RNA, Viral | 1 | 2002 | 326 | 0.210 |
Why?
|
| Drug Evaluation | 1 | 2001 | 144 | 0.210 |
Why?
|
| Hematinics | 1 | 2020 | 9 | 0.210 |
Why?
|
| Delusions | 2 | 2000 | 10 | 0.210 |
Why?
|
| Thrombosis | 2 | 2020 | 265 | 0.210 |
Why?
|
| Health Education | 2 | 2014 | 100 | 0.210 |
Why?
|
| Mathematics | 3 | 2012 | 185 | 0.210 |
Why?
|
| Tablets | 5 | 2009 | 107 | 0.210 |
Why?
|
| Dehydroepiandrosterone | 1 | 2000 | 51 | 0.210 |
Why?
|
| Digestive System | 2 | 2000 | 43 | 0.210 |
Why?
|
| Sulfhydryl Compounds | 2 | 2011 | 68 | 0.210 |
Why?
|
| Social Behavior | 3 | 2019 | 288 | 0.210 |
Why?
|
| Kidney | 1 | 2006 | 1169 | 0.210 |
Why?
|
| Outpatients | 1 | 2021 | 81 | 0.210 |
Why?
|
| Dyskinesia, Drug-Induced | 4 | 2007 | 19 | 0.200 |
Why?
|
| Case-Control Studies | 6 | 2016 | 1722 | 0.200 |
Why?
|
| Early Diagnosis | 2 | 2018 | 125 | 0.200 |
Why?
|
| Plant Oils | 2 | 2013 | 11 | 0.200 |
Why?
|
| Warfarin | 2 | 2017 | 101 | 0.200 |
Why?
|
| Cross-Cultural Comparison | 3 | 2009 | 34 | 0.200 |
Why?
|
| Serum Albumin | 1 | 2020 | 132 | 0.200 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2013 | 148 | 0.200 |
Why?
|
| Oocyte Donation | 1 | 1999 | 2 | 0.200 |
Why?
|
| Benzaldehydes | 2 | 2011 | 4 | 0.200 |
Why?
|
| Lipoproteins, VLDL | 5 | 2016 | 38 | 0.200 |
Why?
|
| Educational Status | 5 | 2008 | 167 | 0.200 |
Why?
|
| MMPI | 1 | 1999 | 11 | 0.200 |
Why?
|
| Oximes | 2 | 2011 | 16 | 0.200 |
Why?
|
| Cisplatin | 3 | 1997 | 579 | 0.200 |
Why?
|
| Heterozygote | 3 | 2018 | 352 | 0.200 |
Why?
|
| Drug Discovery | 2 | 2011 | 95 | 0.200 |
Why?
|
| Cyclosporine | 2 | 2003 | 240 | 0.200 |
Why?
|
| Myosin Type II | 3 | 2015 | 46 | 0.200 |
Why?
|
| Inulin | 1 | 1999 | 17 | 0.190 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2011 | 140 | 0.190 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2010 | 214 | 0.190 |
Why?
|
| Postprandial Period | 3 | 2014 | 46 | 0.190 |
Why?
|
| Streptococcus pneumoniae | 5 | 1996 | 46 | 0.190 |
Why?
|
| Mixed Function Oxygenases | 1 | 2000 | 65 | 0.190 |
Why?
|
| Fibric Acids | 2 | 2016 | 2 | 0.190 |
Why?
|
| Internet | 2 | 2018 | 303 | 0.190 |
Why?
|
| Inflammation Mediators | 3 | 2009 | 151 | 0.190 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2000 | 78 | 0.190 |
Why?
|
| Problem Solving | 2 | 2012 | 51 | 0.190 |
Why?
|
| Food, Formulated | 2 | 1996 | 24 | 0.190 |
Why?
|
| Memory Disorders | 3 | 2015 | 59 | 0.190 |
Why?
|
| Depressive Disorder | 4 | 2002 | 215 | 0.190 |
Why?
|
| Cholesterol, Dietary | 4 | 2003 | 37 | 0.190 |
Why?
|
| Fatty Acids, Unsaturated | 3 | 2013 | 31 | 0.190 |
Why?
|
| Least-Squares Analysis | 4 | 2014 | 46 | 0.190 |
Why?
|
| Minocycline | 1 | 2018 | 15 | 0.180 |
Why?
|
| Nutrition Policy | 1 | 2018 | 12 | 0.180 |
Why?
|
| Mass Screening | 3 | 2017 | 587 | 0.180 |
Why?
|
| Intra-Abdominal Fat | 2 | 2009 | 30 | 0.180 |
Why?
|
| Extracellular Matrix | 3 | 2015 | 224 | 0.180 |
Why?
|
| Isoenzymes | 3 | 2006 | 269 | 0.180 |
Why?
|
| International Classification of Diseases | 3 | 2009 | 64 | 0.180 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2018 | 7 | 0.180 |
Why?
|
| Receptors, sigma | 1 | 2018 | 6 | 0.180 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2018 | 41 | 0.180 |
Why?
|
| Nutritional Requirements | 1 | 1998 | 17 | 0.180 |
Why?
|
| Mutation | 9 | 2018 | 3745 | 0.180 |
Why?
|
| Creatine Kinase | 5 | 2007 | 48 | 0.180 |
Why?
|
| Models, Biological | 5 | 2015 | 1724 | 0.180 |
Why?
|
| Food Labeling | 1 | 1998 | 8 | 0.180 |
Why?
|
| Combined Modality Therapy | 5 | 2013 | 1602 | 0.180 |
Why?
|
| Fruit | 1 | 1998 | 71 | 0.180 |
Why?
|
| Esophagogastric Junction | 1 | 2018 | 31 | 0.180 |
Why?
|
| Apolipoproteins E | 2 | 2005 | 115 | 0.180 |
Why?
|
| Oxazepines | 2 | 2009 | 4 | 0.180 |
Why?
|
| Lipid Peroxidation | 2 | 2009 | 41 | 0.180 |
Why?
|
| Antiviral Agents | 1 | 2002 | 489 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2014 | 168 | 0.170 |
Why?
|
| Alanine Transaminase | 3 | 2010 | 70 | 0.170 |
Why?
|
| Indoleacetic Acids | 2 | 2009 | 7 | 0.170 |
Why?
|
| Genome-Wide Association Study | 4 | 2018 | 1471 | 0.170 |
Why?
|
| Orientation | 2 | 1995 | 116 | 0.170 |
Why?
|
| Drug Labeling | 1 | 2018 | 40 | 0.170 |
Why?
|
| Nicotinic Agonists | 1 | 1998 | 66 | 0.170 |
Why?
|
| Weight Loss | 4 | 2002 | 222 | 0.170 |
Why?
|
| Logistic Models | 6 | 2015 | 1113 | 0.170 |
Why?
|
| Myocardium | 3 | 2014 | 520 | 0.170 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2018 | 39 | 0.170 |
Why?
|
| Verbal Behavior | 2 | 1997 | 30 | 0.170 |
Why?
|
| Fibroblasts | 3 | 2015 | 695 | 0.170 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 38 | 0.170 |
Why?
|
| Piperazines | 4 | 1994 | 266 | 0.170 |
Why?
|
| Bezafibrate | 2 | 2009 | 5 | 0.170 |
Why?
|
| Hospitals, State | 1 | 1997 | 2 | 0.170 |
Why?
|
| Cerebral Cortex | 6 | 2005 | 550 | 0.170 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 515 | 0.170 |
Why?
|
| Chylomicrons | 1 | 2017 | 12 | 0.170 |
Why?
|
| Geriatric Psychiatry | 1 | 1997 | 17 | 0.170 |
Why?
|
| Phagosomes | 2 | 2014 | 38 | 0.160 |
Why?
|
| Intellectual Disability | 2 | 2015 | 174 | 0.160 |
Why?
|
| Prostate-Specific Antigen | 1 | 2019 | 310 | 0.160 |
Why?
|
| Brain Diseases | 1 | 2018 | 171 | 0.160 |
Why?
|
| Green Fluorescent Proteins | 2 | 2015 | 296 | 0.160 |
Why?
|
| Dietary Proteins | 3 | 1996 | 29 | 0.160 |
Why?
|
| Protein Multimerization | 2 | 2015 | 176 | 0.160 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 2 | 2006 | 7 | 0.160 |
Why?
|
| Physostigmine | 3 | 1994 | 19 | 0.160 |
Why?
|
| Papillomaviridae | 2 | 1997 | 149 | 0.160 |
Why?
|
| Receptors, LDL | 2 | 2014 | 52 | 0.160 |
Why?
|
| Psychosurgery | 2 | 1995 | 14 | 0.160 |
Why?
|
| Suicide, Attempted | 2 | 2015 | 120 | 0.160 |
Why?
|
| Norepinephrine | 3 | 1994 | 168 | 0.160 |
Why?
|
| Psychotropic Drugs | 1 | 1997 | 74 | 0.160 |
Why?
|
| Narcotic Antagonists | 1 | 2018 | 149 | 0.160 |
Why?
|
| Homozygote | 2 | 2014 | 194 | 0.160 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 16 | 0.160 |
Why?
|
| Deinstitutionalization | 1 | 2016 | 2 | 0.150 |
Why?
|
| Paternal Age | 2 | 2006 | 5 | 0.150 |
Why?
|
| DNA, Mitochondrial | 6 | 2001 | 179 | 0.150 |
Why?
|
| 25-Hydroxyvitamin D 2 | 2 | 2014 | 5 | 0.150 |
Why?
|
| Vitamin K 1 | 2 | 2014 | 4 | 0.150 |
Why?
|
| Hepatitis Antibodies | 2 | 1995 | 6 | 0.150 |
Why?
|
| Viral Hepatitis Vaccines | 2 | 1995 | 5 | 0.150 |
Why?
|
| Urban Population | 1 | 1997 | 212 | 0.150 |
Why?
|
| Down-Regulation | 3 | 2019 | 501 | 0.150 |
Why?
|
| Calcifediol | 2 | 2014 | 21 | 0.150 |
Why?
|
| Social Participation | 1 | 2016 | 13 | 0.150 |
Why?
|
| Drug Approval | 2 | 2008 | 60 | 0.150 |
Why?
|
| Chylomicron Remnants | 1 | 2015 | 2 | 0.150 |
Why?
|
| Cathartics | 1 | 1996 | 30 | 0.150 |
Why?
|
| Community Health Planning | 1 | 2015 | 16 | 0.150 |
Why?
|
| Brain | 8 | 1998 | 1998 | 0.150 |
Why?
|
| Radiosurgery | 1 | 2019 | 257 | 0.150 |
Why?
|
| Bone Density | 3 | 2002 | 203 | 0.150 |
Why?
|
| Drug Resistance | 1 | 2016 | 261 | 0.150 |
Why?
|
| Employment | 1 | 2016 | 48 | 0.150 |
Why?
|
| Chemotaxis | 1 | 2016 | 71 | 0.150 |
Why?
|
| Neutropenia | 3 | 2002 | 210 | 0.150 |
Why?
|
| Perfusion Imaging | 1 | 2015 | 43 | 0.150 |
Why?
|
| Immunological Synapses | 1 | 2015 | 5 | 0.150 |
Why?
|
| rho-Associated Kinases | 2 | 2014 | 158 | 0.150 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2006 | 35 | 0.150 |
Why?
|
| Microvessels | 1 | 2015 | 69 | 0.150 |
Why?
|
| Abdomen | 3 | 2009 | 105 | 0.150 |
Why?
|
| Receptors, Dopamine | 4 | 2001 | 40 | 0.140 |
Why?
|
| Patient Safety | 1 | 2018 | 206 | 0.140 |
Why?
|
| Actin Cytoskeleton | 2 | 2014 | 175 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 1 | 6 | 2010 | 535 | 0.140 |
Why?
|
| Anti-Anxiety Agents | 2 | 1994 | 22 | 0.140 |
Why?
|
| Confidence Intervals | 3 | 2009 | 223 | 0.140 |
Why?
|
| Ultrasonics | 1 | 2015 | 32 | 0.140 |
Why?
|
| Actomyosin | 1 | 2015 | 39 | 0.140 |
Why?
|
| Curriculum | 2 | 2009 | 472 | 0.140 |
Why?
|
| Psychomotor Disorders | 1 | 2015 | 20 | 0.140 |
Why?
|
| beta Carotene | 1 | 2014 | 4 | 0.140 |
Why?
|
| Microspheres | 1 | 2015 | 89 | 0.140 |
Why?
|
| Endocrinology | 1 | 2017 | 64 | 0.140 |
Why?
|
| Prothrombin | 1 | 2014 | 14 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 397 | 0.140 |
Why?
|
| beta-Alanine | 1 | 2014 | 8 | 0.140 |
Why?
|
| alpha-Tocopherol | 1 | 2014 | 9 | 0.140 |
Why?
|
| Immunosuppressive Agents | 2 | 2003 | 978 | 0.140 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2015 | 86 | 0.140 |
Why?
|
| Cytoplasmic Granules | 1 | 2015 | 93 | 0.140 |
Why?
|
| Vitamin A | 1 | 2014 | 27 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 283 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 302 | 0.140 |
Why?
|
| Myocardial Revascularization | 3 | 2013 | 31 | 0.140 |
Why?
|
| Receptors, Prostaglandin | 3 | 2009 | 7 | 0.140 |
Why?
|
| Immunization, Secondary | 1 | 1994 | 26 | 0.140 |
Why?
|
| Quantum Dots | 1 | 2014 | 17 | 0.140 |
Why?
|
| Phospholipids | 5 | 2015 | 108 | 0.140 |
Why?
|
| Reoperation | 3 | 2014 | 562 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2010 | 2439 | 0.140 |
Why?
|
| Glycocalyx | 1 | 2014 | 2 | 0.140 |
Why?
|
| Vasa Vasorum | 1 | 2014 | 5 | 0.140 |
Why?
|
| Immunologic Memory | 1 | 2016 | 145 | 0.140 |
Why?
|
| Genotype | 7 | 2020 | 1776 | 0.140 |
Why?
|
| Placebo Effect | 4 | 2016 | 29 | 0.140 |
Why?
|
| Gene Transfer Techniques | 1 | 2015 | 148 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 2 | 2014 | 489 | 0.140 |
Why?
|
| Plasmids | 1 | 2015 | 282 | 0.140 |
Why?
|
| Length of Stay | 5 | 2013 | 647 | 0.140 |
Why?
|
| Uterine Cervicitis | 1 | 1994 | 5 | 0.140 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 1994 | 10 | 0.130 |
Why?
|
| Heart Failure | 3 | 2011 | 1075 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 2268 | 0.130 |
Why?
|
| Postoperative Hemorrhage | 1 | 2014 | 43 | 0.130 |
Why?
|
| src-Family Kinases | 1 | 2014 | 74 | 0.130 |
Why?
|
| Cholinergic Fibers | 2 | 1991 | 23 | 0.130 |
Why?
|
| Disease-Free Survival | 5 | 2015 | 1175 | 0.130 |
Why?
|
| Myristic Acid | 1 | 2014 | 2 | 0.130 |
Why?
|
| p21-Activated Kinases | 1 | 2014 | 15 | 0.130 |
Why?
|
| Overweight | 2 | 2013 | 106 | 0.130 |
Why?
|
| Receptors, AMPA | 1 | 2014 | 67 | 0.130 |
Why?
|
| Withholding Treatment | 2 | 2013 | 109 | 0.130 |
Why?
|
| Protein Precursors | 1 | 2014 | 143 | 0.130 |
Why?
|
| Cell Line, Tumor | 4 | 2014 | 2320 | 0.130 |
Why?
|
| Jews | 2 | 2008 | 42 | 0.130 |
Why?
|
| Depression | 2 | 1998 | 405 | 0.130 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 103 | 0.130 |
Why?
|
| Executive Function | 1 | 2015 | 78 | 0.130 |
Why?
|
| Fatty Acid Desaturases | 1 | 2013 | 16 | 0.130 |
Why?
|
| Cell Shape | 1 | 2014 | 50 | 0.130 |
Why?
|
| Low Back Pain | 1 | 2014 | 35 | 0.130 |
Why?
|
| Amides | 2 | 2011 | 57 | 0.130 |
Why?
|
| Lectins, C-Type | 1 | 2014 | 92 | 0.130 |
Why?
|
| Weight Gain | 3 | 2005 | 125 | 0.130 |
Why?
|
| Aneurysm, Dissecting | 1 | 2014 | 91 | 0.130 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2014 | 84 | 0.130 |
Why?
|
| Tumor Virus Infections | 1 | 1994 | 80 | 0.130 |
Why?
|
| Absorption | 1 | 2013 | 25 | 0.130 |
Why?
|
| Receptors, Immunologic | 3 | 2009 | 134 | 0.130 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2014 | 76 | 0.130 |
Why?
|
| Fungi | 1 | 2014 | 61 | 0.130 |
Why?
|
| Stress, Physiological | 1 | 2015 | 224 | 0.130 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2006 | 42 | 0.130 |
Why?
|
| Glycine | 1 | 2014 | 88 | 0.130 |
Why?
|
| Motor Activity | 3 | 2005 | 321 | 0.130 |
Why?
|
| Collagen | 1 | 2015 | 262 | 0.130 |
Why?
|
| Clinical Competence | 2 | 2009 | 700 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2015 | 312 | 0.130 |
Why?
|
| Caspase 3 | 1 | 2014 | 160 | 0.130 |
Why?
|
| Endpoint Determination | 1 | 2013 | 59 | 0.130 |
Why?
|
| Exercise | 3 | 2014 | 277 | 0.130 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2013 | 47 | 0.130 |
Why?
|
| Bioprosthesis | 1 | 2013 | 36 | 0.130 |
Why?
|
| Clonidine | 2 | 1994 | 39 | 0.130 |
Why?
|
| Purines | 1 | 2013 | 98 | 0.130 |
Why?
|
| Dexmedetomidine | 1 | 2013 | 8 | 0.130 |
Why?
|
| Receptors, Dopamine D2 | 1 | 1993 | 46 | 0.130 |
Why?
|
| Midazolam | 1 | 2013 | 50 | 0.130 |
Why?
|
| Vascular Surgical Procedures | 1 | 2014 | 145 | 0.130 |
Why?
|
| Peer Group | 2 | 2004 | 62 | 0.120 |
Why?
|
| Vaccines, Inactivated | 2 | 1995 | 29 | 0.120 |
Why?
|
| Aortic Valve Stenosis | 1 | 2014 | 115 | 0.120 |
Why?
|
| Heart Valve Prosthesis | 1 | 2013 | 86 | 0.120 |
Why?
|
| Genomics | 1 | 2018 | 630 | 0.120 |
Why?
|
| Chemical Precipitation | 1 | 2012 | 19 | 0.120 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2013 | 60 | 0.120 |
Why?
|
| Ultracentrifugation | 1 | 2012 | 43 | 0.120 |
Why?
|
| Mitochondria | 5 | 1996 | 518 | 0.120 |
Why?
|
| Protein Interaction Mapping | 1 | 2013 | 80 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 142 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2014 | 175 | 0.120 |
Why?
|
| Perphenazine | 1 | 2012 | 2 | 0.120 |
Why?
|
| Hypoglycemia | 2 | 2012 | 101 | 0.120 |
Why?
|
| Proteolysis | 1 | 2013 | 96 | 0.120 |
Why?
|
| Romania | 1 | 2012 | 4 | 0.120 |
Why?
|
| Feces | 2 | 2013 | 292 | 0.120 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2014 | 238 | 0.120 |
Why?
|
| Heart Valve Diseases | 1 | 2013 | 97 | 0.120 |
Why?
|
| Conscious Sedation | 1 | 2013 | 67 | 0.120 |
Why?
|
| Foam Cells | 2 | 2009 | 17 | 0.120 |
Why?
|
| Dextran Sulfate | 1 | 2012 | 67 | 0.120 |
Why?
|
| Parietal Lobe | 1 | 1993 | 107 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 2 | 2013 | 142 | 0.120 |
Why?
|
| Treatment Failure | 3 | 2010 | 281 | 0.120 |
Why?
|
| Lipoprotein Lipase | 2 | 2020 | 13 | 0.120 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2012 | 39 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2013 | 149 | 0.120 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2011 | 23 | 0.120 |
Why?
|
| Morbidity | 2 | 2010 | 135 | 0.120 |
Why?
|
| Aspartate Aminotransferases | 2 | 2010 | 69 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2011 | 177 | 0.120 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2013 | 146 | 0.120 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 408 | 0.120 |
Why?
|
| Ventricular Function, Left | 4 | 2013 | 559 | 0.120 |
Why?
|
| Health Status Indicators | 2 | 2009 | 97 | 0.120 |
Why?
|
| Sweden | 3 | 2013 | 41 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 7 | 2017 | 418 | 0.120 |
Why?
|
| Molecular Structure | 2 | 2012 | 283 | 0.120 |
Why?
|
| Hepatovirus | 1 | 1992 | 1 | 0.120 |
Why?
|
| Antisocial Personality Disorder | 1 | 2013 | 88 | 0.120 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2011 | 1 | 0.120 |
Why?
|
| Reference Standards | 1 | 2012 | 142 | 0.110 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2014 | 176 | 0.110 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2013 | 145 | 0.110 |
Why?
|
| Photochemical Processes | 1 | 2011 | 12 | 0.110 |
Why?
|
| Causality | 2 | 2007 | 79 | 0.110 |
Why?
|
| Verbal Learning | 4 | 2013 | 27 | 0.110 |
Why?
|
| HeLa Cells | 5 | 2014 | 497 | 0.110 |
Why?
|
| Osteoporosis, Postmenopausal | 2 | 2002 | 34 | 0.110 |
Why?
|
| Serine | 1 | 2012 | 98 | 0.110 |
Why?
|
| Hyperlipoproteinemias | 1 | 1991 | 7 | 0.110 |
Why?
|
| Apolipoprotein E4 | 3 | 2020 | 13 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2013 | 117 | 0.110 |
Why?
|
| Hypnotics and Sedatives | 1 | 2013 | 126 | 0.110 |
Why?
|
| Behavior | 2 | 1994 | 86 | 0.110 |
Why?
|
| Mice | 9 | 2015 | 10710 | 0.110 |
Why?
|
| Alendronate | 2 | 2002 | 11 | 0.110 |
Why?
|
| Substance-Related Disorders | 2 | 2013 | 363 | 0.110 |
Why?
|
| Venoms | 1 | 2011 | 12 | 0.110 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2011 | 12 | 0.110 |
Why?
|
| Neoplasm Staging | 5 | 2015 | 1858 | 0.110 |
Why?
|
| Gastric Emptying | 1 | 2011 | 22 | 0.110 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 287 | 0.110 |
Why?
|
| RNA, Messenger | 3 | 2015 | 1920 | 0.110 |
Why?
|
| Mitral Valve | 1 | 2013 | 232 | 0.110 |
Why?
|
| Motor Cortex | 1 | 1993 | 189 | 0.110 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 89 | 0.110 |
Why?
|
| Hydrocortisone | 5 | 2000 | 289 | 0.110 |
Why?
|
| Sitosterols | 1 | 2011 | 3 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2015 | 619 | 0.110 |
Why?
|
| Calcium | 2 | 2007 | 1122 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2014 | 385 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 366 | 0.110 |
Why?
|
| Cause of Death | 3 | 2004 | 269 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2014 | 376 | 0.110 |
Why?
|
| Quinazolinones | 1 | 2011 | 13 | 0.110 |
Why?
|
| Receptors, CCR2 | 1 | 2011 | 34 | 0.110 |
Why?
|
| Diet, High-Fat | 1 | 2012 | 101 | 0.110 |
Why?
|
| Chemokine CCL2 | 1 | 2011 | 45 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 1994 | 226 | 0.110 |
Why?
|
| Up-Regulation | 2 | 2015 | 688 | 0.110 |
Why?
|
| Steroid 11-beta-Hydroxylase | 1 | 2010 | 1 | 0.110 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1991 | 45 | 0.110 |
Why?
|
| Macrophages | 1 | 2014 | 529 | 0.100 |
Why?
|
| Receptors, Cholinergic | 1 | 1991 | 76 | 0.100 |
Why?
|
| Health Personnel | 2 | 1995 | 176 | 0.100 |
Why?
|
| Energy Intake | 2 | 2002 | 92 | 0.100 |
Why?
|
| Child, Preschool | 5 | 2012 | 3544 | 0.100 |
Why?
|
| RNA, Transfer, Leu | 4 | 1995 | 11 | 0.100 |
Why?
|
| Psychomotor Agitation | 2 | 2005 | 26 | 0.100 |
Why?
|
| Methylcellulose | 2 | 2000 | 6 | 0.100 |
Why?
|
| Long-Term Care | 2 | 2001 | 58 | 0.100 |
Why?
|
| Discriminant Analysis | 2 | 2002 | 64 | 0.100 |
Why?
|
| Self Care | 4 | 2019 | 151 | 0.100 |
Why?
|
| Insurance Claim Review | 1 | 2010 | 37 | 0.100 |
Why?
|
| Therapeutic Equivalency | 2 | 2008 | 11 | 0.100 |
Why?
|
| Polyphenols | 1 | 2009 | 13 | 0.100 |
Why?
|
| Recombinant Proteins | 2 | 2002 | 1015 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 4 | 2014 | 140 | 0.100 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2009 | 5 | 0.100 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2009 | 11 | 0.100 |
Why?
|
| Phenols | 1 | 2009 | 38 | 0.100 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2009 | 13 | 0.100 |
Why?
|
| Waist Circumference | 1 | 2009 | 20 | 0.100 |
Why?
|
| Receptors, Serotonin | 3 | 1994 | 35 | 0.100 |
Why?
|
| Folic Acid | 1 | 2009 | 47 | 0.100 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2006 | 79 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 359 | 0.100 |
Why?
|
| Administration, Cutaneous | 2 | 1999 | 50 | 0.100 |
Why?
|
| Neurons | 3 | 2014 | 1471 | 0.100 |
Why?
|
| Canada | 3 | 2008 | 194 | 0.090 |
Why?
|
| Membrane Proteins | 3 | 2010 | 1161 | 0.090 |
Why?
|
| Health Maintenance Organizations | 1 | 2009 | 20 | 0.090 |
Why?
|
| Flavonoids | 1 | 2009 | 80 | 0.090 |
Why?
|
| Dementia, Vascular | 2 | 2005 | 4 | 0.090 |
Why?
|
| Factor Analysis, Statistical | 4 | 2015 | 100 | 0.090 |
Why?
|
| Suture Techniques | 1 | 2010 | 126 | 0.090 |
Why?
|
| Computers, Handheld | 1 | 2009 | 32 | 0.090 |
Why?
|
| Judaism | 1 | 2008 | 5 | 0.090 |
Why?
|
| Single-Blind Method | 3 | 2002 | 149 | 0.090 |
Why?
|
| Intermittent Claudication | 2 | 1998 | 17 | 0.090 |
Why?
|
| Liver Failure | 2 | 2006 | 78 | 0.090 |
Why?
|
| Diarrhea | 3 | 2005 | 177 | 0.090 |
Why?
|
| Synaptic Transmission | 1 | 2010 | 228 | 0.090 |
Why?
|
| Cytochrome b Group | 1 | 1988 | 10 | 0.090 |
Why?
|
| Bacillus | 1 | 1988 | 11 | 0.090 |
Why?
|
| Hippocampus | 3 | 2005 | 414 | 0.090 |
Why?
|
| Age Distribution | 2 | 2007 | 200 | 0.090 |
Why?
|
| Renal Insufficiency | 2 | 2006 | 105 | 0.090 |
Why?
|
| Ischemic Attack, Transient | 1 | 2010 | 168 | 0.090 |
Why?
|
| Microfilament Proteins | 1 | 2010 | 204 | 0.090 |
Why?
|
| Drosophila melanogaster | 1 | 2013 | 582 | 0.090 |
Why?
|
| Subcutaneous Fat | 1 | 2008 | 16 | 0.090 |
Why?
|
| Cytochrome c Group | 1 | 1988 | 82 | 0.090 |
Why?
|
| Antioxidants | 1 | 2009 | 213 | 0.090 |
Why?
|
| Drug Design | 1 | 2008 | 120 | 0.090 |
Why?
|
| Particle Size | 2 | 2006 | 115 | 0.090 |
Why?
|
| Microscopy, Confocal | 3 | 2015 | 269 | 0.090 |
Why?
|
| Medroxyprogesterone Acetate | 3 | 2002 | 18 | 0.090 |
Why?
|
| Liver Diseases | 2 | 2006 | 224 | 0.090 |
Why?
|
| Tetrazoles | 2 | 1998 | 49 | 0.090 |
Why?
|
| Dyslexia | 1 | 2007 | 9 | 0.090 |
Why?
|
| Cell Line | 6 | 2015 | 2470 | 0.090 |
Why?
|
| Monocytes | 1 | 2009 | 220 | 0.090 |
Why?
|
| Personality Disorders | 3 | 2001 | 140 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 3069 | 0.080 |
Why?
|
| Triticum | 1 | 2007 | 30 | 0.080 |
Why?
|
| Hormones | 1 | 1988 | 129 | 0.080 |
Why?
|
| Chicago | 2 | 2009 | 1327 | 0.080 |
Why?
|
| New York | 2 | 1997 | 64 | 0.080 |
Why?
|
| Cat Diseases | 1 | 2007 | 20 | 0.080 |
Why?
|
| Coffee | 1 | 2007 | 10 | 0.080 |
Why?
|
| Probability | 3 | 2010 | 345 | 0.080 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2008 | 83 | 0.080 |
Why?
|
| Socioeconomic Factors | 3 | 2005 | 535 | 0.080 |
Why?
|
| Protein Binding | 4 | 2015 | 1447 | 0.080 |
Why?
|
| Acute Disease | 3 | 2006 | 802 | 0.080 |
Why?
|
| Dog Diseases | 1 | 2007 | 35 | 0.080 |
Why?
|
| Comprehension | 1 | 2007 | 67 | 0.080 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 1998 | 113 | 0.080 |
Why?
|
| Myocardial Infarction | 5 | 2013 | 344 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 991 | 0.080 |
Why?
|
| Point Mutation | 4 | 2013 | 246 | 0.080 |
Why?
|
| Neurologic Examination | 1 | 2007 | 110 | 0.080 |
Why?
|
| Societies, Medical | 4 | 2017 | 565 | 0.080 |
Why?
|
| Dibenzothiazepines | 1 | 2006 | 4 | 0.080 |
Why?
|
| Attention | 5 | 1995 | 359 | 0.080 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2006 | 12 | 0.080 |
Why?
|
| Residence Characteristics | 3 | 2012 | 186 | 0.080 |
Why?
|
| Religion and Medicine | 1 | 2008 | 120 | 0.080 |
Why?
|
| Biotransformation | 1 | 2006 | 52 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 302 | 0.080 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2006 | 30 | 0.080 |
Why?
|
| Nausea | 2 | 2005 | 168 | 0.080 |
Why?
|
| Mitral Valve Prolapse | 1 | 1986 | 22 | 0.080 |
Why?
|
| Glucose Tolerance Test | 1 | 2007 | 229 | 0.080 |
Why?
|
| Lipogenesis | 1 | 2006 | 21 | 0.080 |
Why?
|
| Rats | 5 | 2014 | 3921 | 0.080 |
Why?
|
| Sexual Behavior | 2 | 2002 | 266 | 0.080 |
Why?
|
| Body Temperature | 4 | 1999 | 116 | 0.080 |
Why?
|
| Blood Proteins | 2 | 2003 | 142 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 159 | 0.070 |
Why?
|
| Managed Care Programs | 1 | 2006 | 41 | 0.070 |
Why?
|
| Administration, Inhalation | 1 | 2006 | 180 | 0.070 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2005 | 2 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2013 | 2067 | 0.070 |
Why?
|
| Immunoglobulin G | 3 | 2013 | 442 | 0.070 |
Why?
|
| Agranulocytosis | 1 | 1985 | 20 | 0.070 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 2014 | 48 | 0.070 |
Why?
|
| Creatinine | 1 | 2006 | 330 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 1998 | 921 | 0.070 |
Why?
|
| Capsules | 1 | 2005 | 36 | 0.070 |
Why?
|
| Autistic Disorder | 1 | 2006 | 138 | 0.070 |
Why?
|
| Epidemiologic Research Design | 1 | 2005 | 22 | 0.070 |
Why?
|
| Ambulatory Care | 2 | 2017 | 168 | 0.070 |
Why?
|
| Body Size | 1 | 2006 | 83 | 0.070 |
Why?
|
| Colestipol | 2 | 1995 | 3 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2013 | 845 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 334 | 0.070 |
Why?
|
| Viscosity | 3 | 2000 | 45 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2011 | 2254 | 0.070 |
Why?
|
| Creatine Kinase, MM Form | 1 | 2004 | 1 | 0.070 |
Why?
|
| Spermatozoa | 1 | 2005 | 63 | 0.070 |
Why?
|
| Serotonin | 4 | 1994 | 218 | 0.070 |
Why?
|
| Muscles | 1 | 1985 | 186 | 0.070 |
Why?
|
| Inpatients | 3 | 2016 | 264 | 0.070 |
Why?
|
| Heart | 3 | 1998 | 498 | 0.070 |
Why?
|
| Carotenoids | 2 | 2001 | 15 | 0.070 |
Why?
|
| DNA, Viral | 2 | 1997 | 268 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2006 | 455 | 0.070 |
Why?
|
| Tomography, Emission-Computed | 3 | 1994 | 104 | 0.070 |
Why?
|
| Hyponatremia | 1 | 2004 | 24 | 0.070 |
Why?
|
| Body Height | 1 | 2005 | 98 | 0.070 |
Why?
|
| Home Care Services | 2 | 2003 | 69 | 0.070 |
Why?
|
| Biological Transport, Active | 1 | 2004 | 102 | 0.070 |
Why?
|
| Physical Conditioning, Animal | 1 | 2004 | 18 | 0.070 |
Why?
|
| Pseudopodia | 2 | 2015 | 31 | 0.070 |
Why?
|
| Contrast Media | 2 | 2013 | 1008 | 0.070 |
Why?
|
| ATP Citrate (pro-S)-Lyase | 2 | 2014 | 3 | 0.070 |
Why?
|
| MELAS Syndrome | 2 | 1995 | 3 | 0.070 |
Why?
|
| Mannose-Binding Lectin | 1 | 2004 | 3 | 0.070 |
Why?
|
| Europe | 3 | 2013 | 293 | 0.070 |
Why?
|
| Fatty Liver | 1 | 2005 | 118 | 0.070 |
Why?
|
| Eating | 1 | 2005 | 166 | 0.070 |
Why?
|
| Kidney Tubules | 1 | 2004 | 95 | 0.070 |
Why?
|
| Hormone Replacement Therapy | 2 | 2002 | 70 | 0.070 |
Why?
|
| Bulbar Palsy, Progressive | 1 | 2003 | 1 | 0.070 |
Why?
|
| Serotonin Receptor Agonists | 2 | 1994 | 14 | 0.070 |
Why?
|
| Gout Suppressants | 1 | 2004 | 36 | 0.060 |
Why?
|
| Liver Function Tests | 2 | 2002 | 94 | 0.060 |
Why?
|
| Pressure | 2 | 2014 | 147 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2011 | 488 | 0.060 |
Why?
|
| Physical Examination | 1 | 2004 | 142 | 0.060 |
Why?
|
| Fluorocarbons | 1 | 2004 | 70 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2004 | 347 | 0.060 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2003 | 43 | 0.060 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2014 | 60 | 0.060 |
Why?
|
| Albumins | 1 | 2004 | 118 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 2112 | 0.060 |
Why?
|
| Molecular Sequence Data | 5 | 2015 | 3050 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 2 | 2015 | 420 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2014 | 1094 | 0.060 |
Why?
|
| Security Measures | 1 | 2003 | 3 | 0.060 |
Why?
|
| Commitment of Mentally Ill | 1 | 2003 | 2 | 0.060 |
Why?
|
| Prolactin | 5 | 1994 | 90 | 0.060 |
Why?
|
| Galantamine | 1 | 2003 | 1 | 0.060 |
Why?
|
| Telephone | 1 | 2003 | 29 | 0.060 |
Why?
|
| Molecular Weight | 3 | 2011 | 334 | 0.060 |
Why?
|
| Alcoholism | 3 | 1993 | 159 | 0.060 |
Why?
|
| Clostridium Infections | 1 | 1985 | 112 | 0.060 |
Why?
|
| Social Alienation | 1 | 2002 | 1 | 0.060 |
Why?
|
| Amino Acid Sequence | 4 | 2015 | 2077 | 0.060 |
Why?
|
| Language Tests | 1 | 2002 | 18 | 0.060 |
Why?
|
| Diglycerides | 1 | 2002 | 22 | 0.060 |
Why?
|
| Specialty Boards | 1 | 2003 | 22 | 0.060 |
Why?
|
| Gastrostomy | 1 | 2003 | 65 | 0.060 |
Why?
|
| Apolipoproteins C | 1 | 2002 | 5 | 0.060 |
Why?
|
| Mood Disorders | 2 | 2001 | 76 | 0.060 |
Why?
|
| Diet, Reducing | 1 | 2002 | 31 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2018 | 170 | 0.060 |
Why?
|
| Health Services for the Aged | 1 | 2003 | 26 | 0.060 |
Why?
|
| Achievement | 1 | 2002 | 24 | 0.060 |
Why?
|
| Hospital Units | 1 | 2003 | 30 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2003 | 304 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2015 | 604 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 1 | 2002 | 119 | 0.060 |
Why?
|
| Interview, Psychological | 1 | 2002 | 68 | 0.060 |
Why?
|
| Protein Transport | 2 | 2015 | 406 | 0.060 |
Why?
|
| Cell Survival | 3 | 2014 | 952 | 0.060 |
Why?
|
| Brain Diseases, Metabolic | 2 | 1992 | 9 | 0.060 |
Why?
|
| Serotyping | 3 | 2000 | 29 | 0.060 |
Why?
|
| Infant, Newborn | 4 | 1998 | 2249 | 0.060 |
Why?
|
| COS Cells | 2 | 2014 | 168 | 0.060 |
Why?
|
| Progestins | 1 | 2002 | 22 | 0.060 |
Why?
|
| Psychiatry | 1 | 2003 | 74 | 0.060 |
Why?
|
| Uterine Hemorrhage | 1 | 2002 | 17 | 0.060 |
Why?
|
| Testosterone | 2 | 2000 | 265 | 0.060 |
Why?
|
| Illinois | 1 | 2003 | 446 | 0.060 |
Why?
|
| Neurotic Disorders | 1 | 2001 | 7 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 1032 | 0.060 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2003 | 174 | 0.060 |
Why?
|
| Viral Load | 1 | 2002 | 136 | 0.060 |
Why?
|
| Hypothermia | 1 | 1981 | 24 | 0.060 |
Why?
|
| Esterification | 1 | 2001 | 6 | 0.060 |
Why?
|
| Margarine | 1 | 2001 | 1 | 0.060 |
Why?
|
| Hospitals, Community | 1 | 1981 | 28 | 0.060 |
Why?
|
| Sulfonic Acids | 1 | 2001 | 9 | 0.060 |
Why?
|
| Hemodynamics | 3 | 2013 | 677 | 0.060 |
Why?
|
| Etidronic Acid | 1 | 2001 | 5 | 0.060 |
Why?
|
| Myocytes, Cardiac | 1 | 2004 | 251 | 0.050 |
Why?
|
| Acetates | 1 | 2001 | 68 | 0.050 |
Why?
|
| Somatostatin | 3 | 1996 | 56 | 0.050 |
Why?
|
| Receptors, Histamine | 1 | 2001 | 4 | 0.050 |
Why?
|
| Sickness Impact Profile | 1 | 2001 | 25 | 0.050 |
Why?
|
| Haemophilus influenzae | 2 | 2000 | 13 | 0.050 |
Why?
|
| Motor Neuron Disease | 1 | 2001 | 19 | 0.050 |
Why?
|
| Basal Ganglia Diseases | 1 | 2001 | 9 | 0.050 |
Why?
|
| Immunoglobulin M | 2 | 1998 | 154 | 0.050 |
Why?
|
| Neurofibrillary Tangles | 5 | 2005 | 19 | 0.050 |
Why?
|
| Immunoglobulin A | 2 | 1998 | 82 | 0.050 |
Why?
|
| Autopsy | 2 | 1998 | 98 | 0.050 |
Why?
|
| Arousal | 2 | 1992 | 166 | 0.050 |
Why?
|
| Mitochondria, Heart | 1 | 2001 | 45 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2787 | 0.050 |
Why?
|
| Androsterone | 1 | 2000 | 6 | 0.050 |
Why?
|
| Receptors, Muscarinic | 1 | 2001 | 49 | 0.050 |
Why?
|
| Blood Coagulation Factors | 1 | 2000 | 20 | 0.050 |
Why?
|
| Dihydrotestosterone | 1 | 2000 | 26 | 0.050 |
Why?
|
| Dogs | 2 | 2015 | 694 | 0.050 |
Why?
|
| Adrenal Cortex | 1 | 2000 | 21 | 0.050 |
Why?
|
| Telemedicine | 1 | 2003 | 138 | 0.050 |
Why?
|
| Naphthalenes | 1 | 2001 | 46 | 0.050 |
Why?
|
| Haemophilus Vaccines | 1 | 2000 | 5 | 0.050 |
Why?
|
| Diagnosis, Differential | 4 | 2003 | 1490 | 0.050 |
Why?
|
| Haemophilus Infections | 1 | 2000 | 6 | 0.050 |
Why?
|
| Nutritional Status | 2 | 1999 | 80 | 0.050 |
Why?
|
| Infant | 6 | 2012 | 2924 | 0.050 |
Why?
|
| Infant Nutritional Physiological Phenomena | 2 | 1970 | 19 | 0.050 |
Why?
|
| Immunization Programs | 1 | 2000 | 22 | 0.050 |
Why?
|
| C-Peptide | 1 | 2000 | 167 | 0.050 |
Why?
|
| Acetylation | 1 | 2000 | 121 | 0.050 |
Why?
|
| Acute-Phase Proteins | 1 | 2020 | 33 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2002 | 441 | 0.050 |
Why?
|
| Blood Component Removal | 1 | 2020 | 27 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 2173 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2002 | 182 | 0.050 |
Why?
|
| Congresses as Topic | 1 | 2001 | 117 | 0.050 |
Why?
|
| Lipolysis | 1 | 2020 | 23 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2000 | 56 | 0.050 |
Why?
|
| Endoscopy | 1 | 2003 | 309 | 0.050 |
Why?
|
| Transdermal Patch | 1 | 2019 | 3 | 0.050 |
Why?
|
| Milk | 1 | 1980 | 45 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2000 | 70 | 0.050 |
Why?
|
| Neurites | 2 | 2013 | 34 | 0.050 |
Why?
|
| Aggression | 2 | 2019 | 300 | 0.050 |
Why?
|
| Testis | 1 | 2000 | 153 | 0.050 |
Why?
|
| Affect | 1 | 2002 | 382 | 0.050 |
Why?
|
| Psychomotor Performance | 2 | 1995 | 483 | 0.050 |
Why?
|
| Whole-Body Irradiation | 1 | 1999 | 63 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 3052 | 0.050 |
Why?
|
| Lactose | 1 | 1999 | 27 | 0.050 |
Why?
|
| Poultry | 1 | 1999 | 22 | 0.050 |
Why?
|
| Seafood | 1 | 1999 | 9 | 0.050 |
Why?
|
| Neoplasms | 1 | 2014 | 2618 | 0.050 |
Why?
|
| Endocarditis, Bacterial | 2 | 1992 | 34 | 0.050 |
Why?
|
| Knee Injuries | 1 | 2000 | 50 | 0.050 |
Why?
|
| Infant, Premature | 2 | 1980 | 265 | 0.050 |
Why?
|
| Steroids | 1 | 2000 | 165 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1999 | 41 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 1999 | 37 | 0.050 |
Why?
|
| Motivation | 1 | 2002 | 260 | 0.050 |
Why?
|
| Carbon Monoxide | 1 | 1999 | 94 | 0.050 |
Why?
|
| Gum Arabic | 1 | 1998 | 1 | 0.050 |
Why?
|
| Pectins | 1 | 1998 | 4 | 0.050 |
Why?
|
| Thyroxine | 1 | 2000 | 318 | 0.050 |
Why?
|
| Violence | 1 | 2001 | 118 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2014 | 3144 | 0.050 |
Why?
|
| Mitochondrial Myopathies | 1 | 1998 | 2 | 0.050 |
Why?
|
| Schizotypal Personality Disorder | 2 | 1995 | 6 | 0.050 |
Why?
|
| RNA | 2 | 1993 | 505 | 0.050 |
Why?
|
| Gene Expression | 2 | 2013 | 1278 | 0.050 |
Why?
|
| Cell Membrane | 2 | 2015 | 666 | 0.040 |
Why?
|
| International Cooperation | 2 | 2009 | 124 | 0.040 |
Why?
|
| Decision Trees | 2 | 2013 | 63 | 0.040 |
Why?
|
| Health Status | 1 | 2001 | 342 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2005 | 792 | 0.040 |
Why?
|
| Neuromuscular Diseases | 1 | 1998 | 31 | 0.040 |
Why?
|
| Fever | 1 | 1999 | 121 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 2 | 2013 | 52 | 0.040 |
Why?
|
| Adrenocorticotropic Hormone | 5 | 2000 | 131 | 0.040 |
Why?
|
| Primates | 1 | 2020 | 147 | 0.040 |
Why?
|
| Solubility | 1 | 1998 | 172 | 0.040 |
Why?
|
| African Americans | 1 | 2006 | 1076 | 0.040 |
Why?
|
| Coronary Circulation | 2 | 2015 | 129 | 0.040 |
Why?
|
| Interpersonal Relations | 1 | 2019 | 165 | 0.040 |
Why?
|
| London | 1 | 1997 | 14 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 1981 | 411 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2020 | 236 | 0.040 |
Why?
|
| Anthropometry | 1 | 1997 | 74 | 0.040 |
Why?
|
| Vitamin E | 1 | 1997 | 35 | 0.040 |
Why?
|
| Platelet Function Tests | 1 | 2017 | 9 | 0.040 |
Why?
|
| Peripheral Vascular Diseases | 1 | 1998 | 59 | 0.040 |
Why?
|
| Pedigree | 2 | 2013 | 959 | 0.040 |
Why?
|
| Physical Exertion | 2 | 2004 | 37 | 0.040 |
Why?
|
| Software | 1 | 2002 | 633 | 0.040 |
Why?
|
| Synaptic Vesicles | 1 | 1997 | 30 | 0.040 |
Why?
|
| Temporal Lobe | 2 | 1996 | 146 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2000 | 312 | 0.040 |
Why?
|
| src Homology Domains | 1 | 1997 | 42 | 0.040 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 1998 | 138 | 0.040 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2018 | 124 | 0.040 |
Why?
|
| Psychological Tests | 1 | 1997 | 91 | 0.040 |
Why?
|
| Gyrus Cinguli | 1 | 1997 | 40 | 0.040 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2017 | 7 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1880 | 0.040 |
Why?
|
| Sucrose | 1 | 1997 | 60 | 0.040 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2016 | 6 | 0.040 |
Why?
|
| Hydroxyindoleacetic Acid | 2 | 1994 | 27 | 0.040 |
Why?
|
| Drug Tolerance | 1 | 1997 | 64 | 0.040 |
Why?
|
| Reading | 1 | 1997 | 28 | 0.040 |
Why?
|
| Carrier State | 1 | 1996 | 36 | 0.040 |
Why?
|
| Rhodamines | 1 | 1996 | 19 | 0.040 |
Why?
|
| Nursing Homes | 3 | 2005 | 98 | 0.040 |
Why?
|
| Health Policy | 1 | 1998 | 170 | 0.040 |
Why?
|
| Electron Transport | 1 | 1996 | 67 | 0.040 |
Why?
|
| Cadherins | 1 | 1997 | 143 | 0.040 |
Why?
|
| Blotting, Northern | 2 | 1993 | 256 | 0.040 |
Why?
|
| Coloring Agents | 1 | 1996 | 65 | 0.040 |
Why?
|
| HL-60 Cells | 1 | 2016 | 20 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 1999 | 272 | 0.040 |
Why?
|
| Hepatitis A Vaccines | 2 | 1995 | 3 | 0.040 |
Why?
|
| Hepatitis A Antibodies | 2 | 1995 | 3 | 0.040 |
Why?
|
| Maternal Age | 2 | 2006 | 43 | 0.040 |
Why?
|
| Immunization Schedule | 2 | 1995 | 22 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 1998 | 1722 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2020 | 345 | 0.040 |
Why?
|
| Recurrence | 2 | 2010 | 1105 | 0.040 |
Why?
|
| Polymerization | 1 | 2015 | 31 | 0.040 |
Why?
|
| Twins | 1 | 2015 | 65 | 0.040 |
Why?
|
| Echocardiography | 2 | 2014 | 858 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2015 | 149 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2000 | 797 | 0.040 |
Why?
|
| Cloning, Molecular | 2 | 2013 | 651 | 0.040 |
Why?
|
| Potoroidae | 1 | 2015 | 4 | 0.040 |
Why?
|
| Schools | 1 | 2016 | 59 | 0.040 |
Why?
|
| Siblings | 1 | 2016 | 108 | 0.040 |
Why?
|
| Neuropeptides | 1 | 1996 | 112 | 0.040 |
Why?
|
| Hepatitis A Virus, Human | 1 | 1995 | 1 | 0.040 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2015 | 14 | 0.040 |
Why?
|
| Insulin Coma | 1 | 1995 | 1 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 1996 | 223 | 0.040 |
Why?
|
| Suicidal Ideation | 1 | 2015 | 54 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 1997 | 287 | 0.040 |
Why?
|
| Serial Learning | 1 | 1995 | 6 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 1998 | 294 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1993 | 275 | 0.040 |
Why?
|
| Antithrombins | 1 | 2014 | 12 | 0.040 |
Why?
|
| Hemostatic Techniques | 1 | 2014 | 14 | 0.040 |
Why?
|
| Heart Valve Prolapse | 1 | 2014 | 1 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 244 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2015 | 85 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 1994 | 43 | 0.030 |
Why?
|
| Electroconvulsive Therapy | 1 | 1995 | 25 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 555 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 1994 | 17 | 0.030 |
Why?
|
| Integrin alpha5beta1 | 1 | 2014 | 12 | 0.030 |
Why?
|
| Vitamin D | 1 | 1997 | 252 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1994 | 26 | 0.030 |
Why?
|
| Brain Mapping | 2 | 1995 | 522 | 0.030 |
Why?
|
| Genome, Human | 2 | 2013 | 732 | 0.030 |
Why?
|
| Immobilized Proteins | 1 | 2014 | 14 | 0.030 |
Why?
|
| beta-Glucans | 1 | 2014 | 5 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 80 | 0.030 |
Why?
|
| Acetylcholine | 2 | 1994 | 177 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 318 | 0.030 |
Why?
|
| Nonmuscle Myosin Type IIA | 1 | 2014 | 4 | 0.030 |
Why?
|
| Choline O-Acetyltransferase | 1 | 1994 | 23 | 0.030 |
Why?
|
| Video Recording | 1 | 2015 | 184 | 0.030 |
Why?
|
| Acetylcholinesterase | 1 | 1994 | 46 | 0.030 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2014 | 15 | 0.030 |
Why?
|
| Thiazolidines | 1 | 2014 | 17 | 0.030 |
Why?
|
| Microscopy, Atomic Force | 1 | 2014 | 47 | 0.030 |
Why?
|
| Mucin-1 | 1 | 2014 | 45 | 0.030 |
Why?
|
| Dyneins | 1 | 2014 | 14 | 0.030 |
Why?
|
| Candida albicans | 1 | 2014 | 32 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 1995 | 108 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 357 | 0.030 |
Why?
|
| Actinin | 1 | 2014 | 19 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2015 | 279 | 0.030 |
Why?
|
| Health Care Surveys | 2 | 2006 | 275 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 74 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2015 | 349 | 0.030 |
Why?
|
| Gene Deletion | 2 | 2010 | 328 | 0.030 |
Why?
|
| Environment | 1 | 2015 | 212 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2014 | 63 | 0.030 |
Why?
|
| Collateral Circulation | 1 | 1994 | 34 | 0.030 |
Why?
|
| Models, Animal | 1 | 2015 | 248 | 0.030 |
Why?
|
| Pattern Recognition, Visual | 1 | 1995 | 146 | 0.030 |
Why?
|
| Rural Population | 1 | 1994 | 124 | 0.030 |
Why?
|
| Fibronectins | 1 | 2014 | 91 | 0.030 |
Why?
|
| Receptors, Dopamine D3 | 1 | 1993 | 15 | 0.030 |
Why?
|
| Bacterial Vaccines | 1 | 1993 | 42 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2014 | 116 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 353 | 0.030 |
Why?
|
| Heart Rate | 3 | 1994 | 492 | 0.030 |
Why?
|
| Chlorpromazine | 1 | 2013 | 15 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2013 | 59 | 0.030 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2014 | 120 | 0.030 |
Why?
|
| Lod Score | 1 | 2013 | 150 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2014 | 243 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 700 | 0.030 |
Why?
|
| Receptors, Adrenergic | 1 | 1993 | 14 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2013 | 40 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2013 | 70 | 0.030 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2014 | 71 | 0.030 |
Why?
|
| Herpesvirus 2, Human | 1 | 2013 | 43 | 0.030 |
Why?
|
| Yohimbine | 1 | 1993 | 7 | 0.030 |
Why?
|
| Perfusion | 1 | 2013 | 184 | 0.030 |
Why?
|
| Lysosomes | 1 | 2014 | 108 | 0.030 |
Why?
|
| Sexual Partners | 1 | 1994 | 89 | 0.030 |
Why?
|
| Brain Damage, Chronic | 1 | 1993 | 26 | 0.030 |
Why?
|
| Helicobacter pylori | 1 | 2013 | 35 | 0.030 |
Why?
|
| Genetic Testing | 2 | 2013 | 487 | 0.030 |
Why?
|
| Propensity Score | 1 | 2013 | 133 | 0.030 |
Why?
|
| Asperger Syndrome | 1 | 2012 | 4 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1999 | 808 | 0.030 |
Why?
|
| Chromatography, Gel | 2 | 1994 | 105 | 0.030 |
Why?
|
| Sexually Transmitted Diseases | 1 | 1994 | 76 | 0.030 |
Why?
|
| Contraception | 1 | 1994 | 78 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2014 | 303 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 720 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 112 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1995 | 253 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 433 | 0.030 |
Why?
|
| Body Temperature Regulation | 1 | 1992 | 53 | 0.030 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 1992 | 9 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 286 | 0.030 |
Why?
|
| Gadolinium DTPA | 1 | 2013 | 254 | 0.030 |
Why?
|
| DNA Primers | 1 | 1993 | 542 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2013 | 268 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 299 | 0.030 |
Why?
|
| Peroxidase | 1 | 2012 | 53 | 0.030 |
Why?
|
| Antigens | 1 | 1993 | 239 | 0.030 |
Why?
|
| Base Sequence | 2 | 1993 | 2323 | 0.030 |
Why?
|
| Breast | 1 | 2014 | 265 | 0.030 |
Why?
|
| Carbon Disulfide | 1 | 1972 | 1 | 0.030 |
Why?
|
| Poland | 1 | 2011 | 10 | 0.030 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2012 | 113 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2014 | 250 | 0.030 |
Why?
|
| Netherlands | 1 | 2011 | 17 | 0.030 |
Why?
|
| Neutralization Tests | 1 | 1992 | 74 | 0.030 |
Why?
|
| Linear Models | 2 | 2008 | 401 | 0.030 |
Why?
|
| Transfection | 1 | 2014 | 892 | 0.030 |
Why?
|
| Autophagy | 1 | 2014 | 142 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 1190 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 341 | 0.030 |
Why?
|
| Depression, Chemical | 1 | 1991 | 31 | 0.030 |
Why?
|
| Plaque, Amyloid | 2 | 2005 | 36 | 0.030 |
Why?
|
| Speech Disorders | 1 | 1991 | 17 | 0.030 |
Why?
|
| Adiponectin | 1 | 2011 | 24 | 0.030 |
Why?
|
| Body Constitution | 2 | 2002 | 26 | 0.030 |
Why?
|
| Fluorescence | 1 | 2011 | 99 | 0.030 |
Why?
|
| Memory, Short-Term | 1 | 1995 | 200 | 0.030 |
Why?
|
| Oxazepam | 1 | 1991 | 3 | 0.030 |
Why?
|
| Disability Evaluation | 2 | 2003 | 120 | 0.030 |
Why?
|
| Protein Stability | 1 | 2011 | 99 | 0.030 |
Why?
|
| Proteins | 1 | 1997 | 751 | 0.030 |
Why?
|
| Benztropine | 1 | 1991 | 3 | 0.030 |
Why?
|
| Catalysis | 1 | 2011 | 197 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 2013 | 616 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 441 | 0.030 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2011 | 94 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2013 | 407 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 842 | 0.030 |
Why?
|
| Prostaglandins | 1 | 1991 | 43 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 827 | 0.030 |
Why?
|
| Family | 1 | 1993 | 301 | 0.030 |
Why?
|
| Indomethacin | 1 | 1991 | 60 | 0.030 |
Why?
|
| Glutamine | 1 | 1991 | 71 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1992 | 372 | 0.030 |
Why?
|
| Cattle | 2 | 1982 | 369 | 0.030 |
Why?
|
| Herpesvirus 1, Human | 1 | 2013 | 242 | 0.030 |
Why?
|
| Cytochalasin D | 1 | 2010 | 14 | 0.030 |
Why?
|
| Dexamethasone | 1 | 1992 | 305 | 0.030 |
Why?
|
| Birth Weight | 1 | 1970 | 137 | 0.030 |
Why?
|
| Pregnancy | 3 | 2013 | 2670 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 677 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2015 | 1904 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 1119 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1997 | 1025 | 0.020 |
Why?
|
| Amyloid beta-Peptides | 1 | 1991 | 158 | 0.020 |
Why?
|
| Critical Care | 1 | 2013 | 349 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1992 | 369 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 555 | 0.020 |
Why?
|
| Endosomes | 1 | 2010 | 77 | 0.020 |
Why?
|
| Radioimmunoassay | 3 | 1994 | 159 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 111 | 0.020 |
Why?
|
| Endothelium | 1 | 2009 | 59 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2009 | 17 | 0.020 |
Why?
|
| Brachial Artery | 1 | 2009 | 37 | 0.020 |
Why?
|
| Pollen | 1 | 1990 | 78 | 0.020 |
Why?
|
| Plant Proteins | 1 | 1990 | 124 | 0.020 |
Why?
|
| Vasodilation | 1 | 2009 | 98 | 0.020 |
Why?
|
| Bone and Bones | 2 | 2001 | 254 | 0.020 |
Why?
|
| Endocytosis | 1 | 2010 | 182 | 0.020 |
Why?
|
| Electroencephalography | 1 | 1993 | 669 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2010 | 329 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2008 | 30 | 0.020 |
Why?
|
| Societies, Pharmaceutical | 1 | 2008 | 1 | 0.020 |
Why?
|
| Myocardial Contraction | 2 | 2004 | 240 | 0.020 |
Why?
|
| Isoelectric Point | 1 | 1988 | 16 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 570 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 400 | 0.020 |
Why?
|
| Heparin | 1 | 2009 | 165 | 0.020 |
Why?
|
| Voluntary Health Agencies | 1 | 2008 | 5 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 1988 | 106 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 2013 | 472 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 2007 | 42 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1540 | 0.020 |
Why?
|
| Psychopathology | 1 | 2007 | 23 | 0.020 |
Why?
|
| Growth Hormone | 1 | 1988 | 97 | 0.020 |
Why?
|
| Plasma | 2 | 1965 | 49 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2008 | 123 | 0.020 |
Why?
|
| Electron Transport Complex IV | 2 | 1998 | 46 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 162 | 0.020 |
Why?
|
| Seasons | 1 | 1989 | 235 | 0.020 |
Why?
|
| Interleukins | 1 | 2008 | 132 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 918 | 0.020 |
Why?
|
| Amino Acids | 1 | 1988 | 239 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1988 | 356 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 682 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2009 | 373 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2009 | 466 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1988 | 494 | 0.020 |
Why?
|
| Cats | 1 | 2007 | 297 | 0.020 |
Why?
|
| Thyrotropin | 1 | 1988 | 268 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2009 | 295 | 0.020 |
Why?
|
| Genomic Imprinting | 1 | 2006 | 32 | 0.020 |
Why?
|
| Mortality | 1 | 2008 | 144 | 0.020 |
Why?
|
| Auscultation | 1 | 1986 | 6 | 0.020 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1986 | 14 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 1986 | 38 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 1986 | 64 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 303 | 0.020 |
Why?
|
| Infant Food | 2 | 1980 | 12 | 0.020 |
Why?
|
| Glucose | 1 | 2009 | 603 | 0.020 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1986 | 25 | 0.020 |
Why?
|
| Phenformin | 1 | 1965 | 5 | 0.020 |
Why?
|
| Tolbutamide | 1 | 1965 | 17 | 0.020 |
Why?
|
| Hyperprolactinemia | 1 | 2005 | 5 | 0.020 |
Why?
|
| Homes for the Aged | 1 | 2005 | 23 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 422 | 0.020 |
Why?
|
| Ketone Bodies | 1 | 1965 | 15 | 0.020 |
Why?
|
| Wechsler Scales | 2 | 1995 | 21 | 0.020 |
Why?
|
| Uterus | 1 | 1987 | 204 | 0.020 |
Why?
|
| Necrosis | 1 | 1985 | 190 | 0.020 |
Why?
|
| Blood Specimen Collection | 1 | 1965 | 27 | 0.020 |
Why?
|
| Drug Therapy | 1 | 1965 | 70 | 0.020 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2004 | 6 | 0.020 |
Why?
|
| Cadaver | 1 | 2005 | 177 | 0.020 |
Why?
|
| Body Water | 1 | 2004 | 38 | 0.020 |
Why?
|
| Hybrid Cells | 2 | 1996 | 72 | 0.020 |
Why?
|
| Methoxyhydroxyphenylglycol | 2 | 1994 | 18 | 0.020 |
Why?
|
| Water-Electrolyte Balance | 1 | 2004 | 67 | 0.020 |
Why?
|
| Dietary Sucrose | 1 | 2004 | 13 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 1986 | 189 | 0.020 |
Why?
|
| Hyperinsulinism | 1 | 2004 | 50 | 0.020 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2004 | 12 | 0.020 |
Why?
|
| Tyrosine | 2 | 1997 | 137 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2003 | 132 | 0.020 |
Why?
|
| Musculoskeletal Diseases | 1 | 2003 | 34 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2003 | 89 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2004 | 292 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 1985 | 317 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2003 | 98 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2004 | 114 | 0.020 |
Why?
|
| Hip | 1 | 2002 | 18 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2007 | 326 | 0.020 |
Why?
|
| Oxygen Consumption | 2 | 1995 | 234 | 0.010 |
Why?
|
| Social Conditions | 1 | 2002 | 8 | 0.010 |
Why?
|
| Digitalis | 1 | 2002 | 2 | 0.010 |
Why?
|
| Torsades de Pointes | 1 | 2002 | 7 | 0.010 |
Why?
|
| Accidents | 1 | 1981 | 8 | 0.010 |
Why?
|
| Parity | 1 | 2002 | 89 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2002 | 149 | 0.010 |
Why?
|
| Psychosocial Deprivation | 1 | 2001 | 4 | 0.010 |
Why?
|
| Demography | 1 | 2002 | 159 | 0.010 |
Why?
|
| Acetamides | 1 | 2001 | 26 | 0.010 |
Why?
|
| Fertility | 1 | 1982 | 97 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 1075 | 0.010 |
Why?
|
| Pilot Projects | 2 | 1994 | 796 | 0.010 |
Why?
|
| Goals | 1 | 2001 | 47 | 0.010 |
Why?
|
| Caregivers | 1 | 2002 | 132 | 0.010 |
Why?
|
| Poultry Products | 1 | 2000 | 2 | 0.010 |
Why?
|
| Fish Products | 1 | 2000 | 3 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 2000 | 72 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2005 | 568 | 0.010 |
Why?
|
| Hemarthrosis | 1 | 2000 | 2 | 0.010 |
Why?
|
| Horses | 1 | 2000 | 35 | 0.010 |
Why?
|
| Temperature | 1 | 1981 | 392 | 0.010 |
Why?
|
| Medial Collateral Ligament, Knee | 1 | 2000 | 5 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 1980 | 29 | 0.010 |
Why?
|
| Contusions | 1 | 2000 | 9 | 0.010 |
Why?
|
| Posterior Cruciate Ligament | 1 | 2000 | 12 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2000 | 268 | 0.010 |
Why?
|
| Collateral Ligaments | 1 | 2000 | 12 | 0.010 |
Why?
|
| Oxazines | 1 | 1999 | 11 | 0.010 |
Why?
|
| Bone Remodeling | 1 | 2000 | 23 | 0.010 |
Why?
|
| Rupture | 1 | 2000 | 55 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2002 | 295 | 0.010 |
Why?
|
| Menisci, Tibial | 1 | 2000 | 22 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2001 | 119 | 0.010 |
Why?
|
| Diclofenac | 1 | 1999 | 5 | 0.010 |
Why?
|
| Tibia | 1 | 2000 | 75 | 0.010 |
Why?
|
| Anterior Cruciate Ligament | 1 | 2000 | 44 | 0.010 |
Why?
|
| Saimiri | 1 | 1999 | 51 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 1999 | 35 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 1999 | 153 | 0.010 |
Why?
|
| Sulfones | 1 | 1999 | 51 | 0.010 |
Why?
|
| Femur | 1 | 2000 | 105 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 1999 | 99 | 0.010 |
Why?
|
| Arthroscopy | 1 | 2000 | 90 | 0.010 |
Why?
|
| Transaminases | 1 | 1999 | 35 | 0.010 |
Why?
|
| Growth | 1 | 1999 | 44 | 0.010 |
Why?
|
| Sexual Maturation | 1 | 1999 | 36 | 0.010 |
Why?
|
| Cytochrome-c Oxidase Deficiency | 1 | 1998 | 3 | 0.010 |
Why?
|
| Ubiquinone | 1 | 1998 | 10 | 0.010 |
Why?
|
| Mitochondrial Encephalomyopathies | 1 | 1998 | 5 | 0.010 |
Why?
|
| Coenzymes | 1 | 1998 | 6 | 0.010 |
Why?
|
| Community Mental Health Services | 1 | 1998 | 14 | 0.010 |
Why?
|
| Education | 1 | 1999 | 54 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1999 | 316 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1998 | 55 | 0.010 |
Why?
|
| Entorhinal Cortex | 1 | 1998 | 13 | 0.010 |
Why?
|
| Diuretics | 1 | 1998 | 138 | 0.010 |
Why?
|
| Varicose Ulcer | 1 | 1977 | 5 | 0.010 |
Why?
|
| Exercise Tolerance | 1 | 1998 | 47 | 0.010 |
Why?
|